
WGS Stock Forecast & Price Target
WGS Analyst Ratings
Bulls say
GeneDx Holdings Corp has demonstrated substantial growth in its core exome/genome revenue, reporting a remarkable 65% year-over-year increase, which is indicative of robust demand and effective sales strategies. The company's anticipated volume shift towards exome/genome-based panels is projected to enhance average selling prices (ASPs) and gross margins (GMs), with GMs expected to reach 70%-71%, bolstered by a 23% year-over-year increase in core ASPs to $3,850 per test. Furthermore, GeneDx's upward revision of its 2025 revenue guidance to a range of $425-428 million, representing a 39%-40% year-over-year growth, underscores the company's positive outlook and strong market positioning within the precision medicine sector.
Bears say
GeneDx Holdings faces significant financial challenges, with an anticipated quarterly cash burn of approximately $2 million attributed to its Fabric initiative. The company is experiencing a high denial rate of 45% as of Q3'24 despite being contracted with around 80% of health plans, which raises concerns about its ability to secure adequate reimbursement for its genomic testing services. Additionally, the reliance on a limited supply of sequencers and materials, along with potential disruptions in data services, could severely impact GeneDx's operational and financial stability going forward.
This aggregate rating is based on analysts' research of GeneDx Holdings Corp and is not a guaranteed prediction by Public.com or investment advice.
WGS Analyst Forecast & Price Prediction
Start investing in WGS
Order type
Buy in
Order amount
Est. shares
0 shares